Pulmonary Vascular Changes in Patients With Chronic Myeloid Leukemia With Second-line Therapy Dasatinib vs. Nilotinib
Doppler echocardiography at rest will be performed in each patient. Patients without
exercise capacity limitation an exercise test (Doppler echocardiography with spiroergometry)
will be performed. Patients who show elevated SPAP at rest or during exercise (in this study
SPAP ≥ 40 mmHg) or with reduced exercise capacity (peak VO2 < 75%) a right heart
catheterization (RHC) will be suggested. Additionally for the evaluation of exercise
capacity a 6 MWD will be performed. This work- up of patients allows clinical and
hemodynamic evaluation.
Observational
Observational Model: Cohort, Time Perspective: Prospective
systolic pulmonary arterial pressure during exercise (50W)
In patients who undergo stressechocardiography: systolic pulmonary arterial pressure (SPAP) at 50W will be measured and the comparison between patients under dasatinib and nilotinib therapy will be performed.
at baseline
No
Horst Olschewski, MD
Principal Investigator
Medical University of Graz
Austria: Federal Office for Safety in Health Care
24-311 ex 10/11
NCT01805843
July 2012
July 2013
Name | Location |
---|